MA45124A - Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients - Google Patents
Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patientsInfo
- Publication number
- MA45124A MA45124A MA045124A MA45124A MA45124A MA 45124 A MA45124 A MA 45124A MA 045124 A MA045124 A MA 045124A MA 45124 A MA45124 A MA 45124A MA 45124 A MA45124 A MA 45124A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- antibody
- biomarker
- level
- sample
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne un procédé d'identification d'un sujet souffrant d'une leucémie lymphocytaire chronique (llc), d'un lymphome non hodgkinien (lnh), d'un lymphome à petits lymphocytes (lpl) ou d'une leucémie lymphoblastique aiguë (lla) qui est sensible à un traitement avec un anticorps anti-cd19, ledit procédé comprenant : a) la fourniture d'un échantillon de sang obtenu à partir dudit sujet avant le traitement avec ledit anticorps anti-cd19, b) la détermination du taux d'au moins un biomarqueur dans ledit échantillon choisi dans le groupe constitué de : i) le nombre de cellules nk périphériques, et ii) les taux d'expression de cd16 sur les cellules nk périphériques, c) la comparaison du taux dudit au moins un biomarqueur dans ledit échantillon à un niveau de coupure prédéterminé, les taux dudit au moins un biomarqueur égaux ou supérieurs au niveau de coupure prédéterminé étant indicatifs d'un sujet qui bénéficierait d'un traitement avec un anticorps anti-cd19. La présente invention concerne en outre un procédé de sélection d'un patient pour le traitement selon l'invention et l'utilisation d'un anticorps anti-cd19 pour le traitement d'un tel patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885 | 2016-05-30 | ||
| PCT/EP2017/063045 WO2017207574A1 (fr) | 2016-05-30 | 2017-05-30 | Procédés de prédiction de bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45124A true MA45124A (fr) | 2017-12-07 |
| MA45124B1 MA45124B1 (fr) | 2021-05-31 |
Family
ID=56116221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45124A MA45124B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
| MA57021A MA57021B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA57021A MA57021B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20190195879A1 (fr) |
| EP (2) | EP3916392B1 (fr) |
| JP (2) | JP7066639B2 (fr) |
| KR (1) | KR102416144B1 (fr) |
| CN (2) | CN115932265B (fr) |
| AU (1) | AU2017272608B2 (fr) |
| CY (1) | CY1124768T1 (fr) |
| DK (2) | DK3916392T3 (fr) |
| EA (1) | EA201892542A1 (fr) |
| ES (2) | ES2878156T3 (fr) |
| FI (1) | FI3916392T3 (fr) |
| HR (2) | HRP20240670T1 (fr) |
| HU (2) | HUE067450T2 (fr) |
| IL (1) | IL263103B2 (fr) |
| LT (2) | LT3465214T (fr) |
| MA (2) | MA45124B1 (fr) |
| MD (2) | MD3916392T2 (fr) |
| MX (2) | MX388502B (fr) |
| PL (2) | PL3916392T3 (fr) |
| PT (2) | PT3465214T (fr) |
| RS (2) | RS62155B1 (fr) |
| SG (2) | SG10201911958SA (fr) |
| SI (2) | SI3465214T1 (fr) |
| SM (2) | SMT202400204T1 (fr) |
| WO (1) | WO2017207574A1 (fr) |
| ZA (2) | ZA201808647B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| AU2020267823A1 (en) * | 2019-05-03 | 2021-11-11 | Incyte Corporation | Anti-CD19 therapy in patients having a limited number of NK cells |
| TW202525340A (zh) * | 2019-10-31 | 2025-07-01 | 美商英塞特公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| KR20220104176A (ko) * | 2019-10-31 | 2022-07-26 | 모르포시스 아게 | 순차적 항-cd19 요법 |
| WO2021259902A1 (fr) * | 2020-06-22 | 2021-12-30 | Morphosys Ag | Polythérapie antitumorale comprenant un anticorps anti-cd19 et des polypeptides bloquant le point de contrôle immunitaire inné sirpα-cd47 |
| WO2022117799A2 (fr) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Polythérapie anti-cd19 |
| WO2026024668A1 (fr) * | 2024-07-22 | 2026-01-29 | Abbott Laboratories | Procédé de détermination d'un volume d'un liquide dans un échantillon |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| US7320991B2 (en) | 2001-02-27 | 2008-01-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Analogs of thalidomide as potential angiogenesis inhibitors |
| WO2005016326A2 (fr) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2534639C (fr) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anticorps anti-cd19 |
| HUE025945T2 (en) * | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
| CA2611814A1 (fr) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Anticorps cd19 et utilisations |
| ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| DE602007013068D1 (de) * | 2006-09-13 | 2011-04-21 | Glycode | Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper |
| EP2176298B1 (fr) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Procédés et compositions permettant l'inhibition de cellules d'expression du cd32b |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| WO2011147834A1 (fr) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Anticorps contre cd19 et utilisations associées |
| EP2409993A1 (fr) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré |
| EP2409712A1 (fr) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré |
| MX2013005270A (es) * | 2010-11-15 | 2013-10-25 | Medimmune Llc | Terapia combinada para linfomas de limfocitos b. |
| EP2524929A1 (fr) | 2011-05-17 | 2012-11-21 | Sanofi | Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B |
| HRP20220224T1 (hr) * | 2011-08-16 | 2022-04-29 | Morphosys Ag | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom |
| KR20140064873A (ko) * | 2011-08-16 | 2014-05-28 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| WO2013090478A1 (fr) * | 2011-12-12 | 2013-06-20 | Pikamab, Inc | Prédiction de la sensibilité vis-à-vis d'une thérapie de maintenance par anticorps |
| CA2935748A1 (fr) * | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Anticorps rfb4 humanises anti-cd22 |
| AU2015277516A1 (en) * | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| CN107209187B (zh) * | 2014-07-11 | 2021-04-20 | 国立健康与医学研究所 | 用于诊断血液癌症的方法 |
-
2017
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 MD MDE20220770T patent/MD3916392T2/ro unknown
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/fr active Active
- 2017-05-30 MX MX2018014702A patent/MX388502B/es unknown
- 2017-05-30 HU HUE21170716A patent/HUE067450T2/hu unknown
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 SM SM20240204T patent/SMT202400204T1/it unknown
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
- 2017-05-30 CN CN202211271570.5A patent/CN115932265B/zh active Active
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 HR HRP20240670TT patent/HRP20240670T1/hr unknown
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/fr active Active
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active Active
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 PL PL21170716.1T patent/PL3916392T3/pl unknown
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2017-05-30 ES ES21170716T patent/ES2981046T3/es active Active
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 SI SI201731527T patent/SI3916392T1/sl unknown
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 SM SM20210291T patent/SMT202100291T1/it unknown
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/fr not_active Ceased
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-01-15 ZA ZA2021/00296A patent/ZA202100296B/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45124A (fr) | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients | |
| Benguigui et al. | Interferon-stimulated neutrophils as a predictor of immunotherapy response | |
| Varettoni et al. | Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms | |
| Holmgren et al. | Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. | |
| Palm et al. | The norepinephrine‐driven metastasis development of PC‐3 human prostate cancer cells in BALB/c nude mice is inhibited by β‐blockers | |
| Strasser et al. | Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile | |
| Quartuccio et al. | The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study | |
| Sugimori et al. | Origin and fate of blood cells deficient in glycosylphosphatidylinositol‐anchored protein among patients with bone marrow failure | |
| De Winde et al. | Tetraspanin CD37 protects against the development of B cell lymphoma | |
| Galluzzo et al. | IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis | |
| Lau et al. | Genetic association of ankylosing spondylitis with TBX21 influences T-bet and pro-inflammatory cytokine expression in humans and SKG mice as a model of spondyloarthritis | |
| US10725029B2 (en) | Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample | |
| Galatola et al. | Gene expression profile of peripheral blood monocytes: a step towards the molecular diagnosis of celiac disease? | |
| Shinohara et al. | A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction | |
| Angelot‐Delettre et al. | Intracytoplasmic detection of TCL1—but not ILT7—by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis | |
| Nolan et al. | Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B | |
| Wang et al. | Transcriptome analysis of gingival tissues of enamel‐renal syndrome | |
| Dehmel et al. | Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long‐term renal allograft outcome | |
| EP2855516B1 (fr) | Polypeptides activant une inflammation et leurs utilisations | |
| Hartling et al. | Gene variation in IL-7 receptor (IL-7R) α affects IL-7R response in CD4+ T cells in HIV-infected individuals | |
| Li et al. | Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia | |
| Gossmann et al. | A gain-of-function mutation in the Plcg2 gene protects mice from helicobacter felis-induced gastric MALT lymphoma | |
| Walker et al. | The effect of systemic corticosteroid therapy on the expression of toll‐like receptor 2 and toll‐like receptor 4 in the cutaneous lesions of leprosy Type 1 reactions | |
| US10955415B2 (en) | CD247 as a biomarker for assessing the effect of chemotherapeutic and biological drugs | |
| CN109402256B (zh) | 利用多个免疫调控点分子的表达量评价胶质瘤临床预后的系统 |